Diadem Digital Solutions LLC
1010 Naughton Drive
7 articles about Diadem Digital Solutions LLC
Diadem Presents Data at 2023 AAIC® Showing Its AlzoSure® Blood Test Can Identify Patients at High Risk of Significant Cognitive Decline Due to Alzheimer's Disease
Diadem SpA announced that study data being presented at the Alzheimer's Association International Conference® 2023 further strengthens the evidence supporting the prognostic value of Diadem's AlzoSure® Predict blood-based biomarker test, which can accurately identify whether or not individuals over the age of 50 will experience a significant cognitive decline due to AD years before the full onset of symptoms.
Diadem Reports New Data Showing Its AlzoSure® Predict Blood Test Can Accurately Identify "Rapid Progressors" Who Will Develop Alzheimer's Disease Within Two Years
Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease, announced that its researchers have developed computational methods that enable its AlzoSure® Predict prognostic technology to accurately identify individuals who will rapidly progress to AD within two years' time.
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.
Esai, Biogen, Diadem and ProMis all presented their findings on biomarker research at this year's International Conference on Alzheimer's and Parkinson's Diseases.
Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer's Disease
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer's disease, announced top-line interim results from a global clinical validation study of its AlzoSure® Predict prognostic biomarker test, which can accurately predict progression to Alzheimer's disease years before symptoms appear.